<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02166021</url>
  </required_header>
  <id_info>
    <org_study_id>MSCMS-001-IL</org_study_id>
    <nct_id>NCT02166021</nct_id>
  </id_info>
  <brief_title>Optimal Administration Mode of Autologous Mesenchymal Bone Marrow Stem Cells in Active and Progressive Multiple Sclerosis</brief_title>
  <official_title>Phase IIA Trial to Investigate the Optimal Way of Administration (Based on the Immunological, Clinical and Neuroradiological Effects) of Autologous Mesenchymal Bone Marrow Stem Cells (MSC) in Active and Progressive Multiple Sclerosis (MS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dimitrios Karussis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to to evaluate the optimal dosage and the way of administration
      of autologous mesenchymal bone marrow stem cells (MSC) either in maximal proximity of the
      lesions in the CNS or by intrathecal injection to the CSF.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brain MRI</measure>
    <time_frame>Change from baseline brain MRI at12 months following treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunological Response</measure>
    <time_frame>Change from baseline immunological response at12 months following treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurological function</measure>
    <time_frame>Change from baseline in EDSS score at12 months following treatment</time_frame>
    <description>EDSS - Expanded Disability Status Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrophysiological tests</measure>
    <time_frame>At baseline and at 6 and 12 months following treatmentChange from baseline electrophysiological tests at12 months following treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Multiple Sclerosis (MS)</condition>
  <arm_group>
    <arm_group_label>IT- Treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection to IT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV - Treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection to IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IT and IV Treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection to IT and IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal stem cells</intervention_name>
    <arm_group_label>IT- Treated</arm_group_label>
    <arm_group_label>IV - Treated</arm_group_label>
    <arm_group_label>IT and IV Treated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Consenting patients fulfilling the Poser's clinical criteria for definite MS

          2. Age: 25-65, males and females

          3. Duration of disease: &gt;3 years

          4. Progressive form of MS (RPMS, SPMS)

          5. EDSS score of 3.0 - 6.5

          6. Failure to the currently available, registered - first and second line
             immunomodulatory treatments

          7. Evidence for new activity of MS during the 3 months before the injection of MSC.

        Exclusion Criteria:

          1. Patients who were treated with cytotoxic medications during the last 3 months prior to
             the inclusion.

          2. Patients suffering from significant cardiac, renal or hepatic failure or any other
             disease that may risk the patient or interfere with the ability to interpret the
             results

          3. Patients with active infections

          4. Patients with severe cognitive decline or inability to understand and sign the
             informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dimitrios Karussis, MD</last_name>
    <phone>02-6776939</phone>
    <email>karus@cc.huji.ac.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dimitrios Karussis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2014</study_first_posted>
  <last_update_submitted>June 7, 2016</last_update_submitted>
  <last_update_submitted_qc>June 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hadassah Medical Organization</investigator_affiliation>
    <investigator_full_name>Dimitrios Karussis</investigator_full_name>
    <investigator_title>Head of The Center for Multiple Sclerosis &amp; Laboratory of Neuroimmunology</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis (MS)</keyword>
  <keyword>Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

